Neurogene Inc. (NGNE) stock analysis

In our weekly check, Neurogene Inc. is graded F (A to F). Of 19 checks on debt, profit, cash flow and trend: 3 pass, warnings: 4, red flags: 12.

Sector: Healthcare · Biotechnology

Strengths

• Low debt

Warning signs

• Weak interest cover
• Weak EPS growth
• Thin margins
• Weak free cash flow
• Very volatile

Next earnings report: 2026-11-12

Similar companies

RGNX · SPRY · TECX · EDIT · ARCT · KYTX

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-10

Open the full analysis